Elisa Oltra, aka Elisa Oltra Garcia, PhD., is a professor of Cell and Molecular Biology at the Universidad Católica de Valencia "San Vicente Mártir", Valencia, Spain. Her areas of research include stem cell, cancer, fibromyalgia and genetics.
2017 Ramsay Award[edit | edit source]
A team comprised of Dr. Elisa Oltra of Universidad Católica de Valencia, Spain, and Drs. Lubov Nathanson, Vladimir Beljanski and Malav Suchin Trivedi of Nova Southeastern University, US, were awarded a 2017 Ramsay Award grant from the Solve ME/CFS Initiative for researching the effect of ME/CFS on epigenetic regulation in specific immune cell types.
Committees and working groups[edit | edit source]
ME/CFS Common Data Element (CDE) Project[edit | edit source]
Chair of the Biomarkers Working Group and a member of the Baseline/Covariate Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control & Prevention.
EUROMENE[edit | edit source]
Participating member of the Biomarkers Working Group of EUROMENE, a European Union, COST Action CA15111, not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Notable studies[edit | edit source]
- 2017, The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE - (Full Text)
- 2018, Identification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-associated DNA methylation patterns - (Full Text)
- 2018, Unraveling the Molecular Determinants of Manual Therapy: An Approach to Integrative Therapeutics for the Treatment of Fibromyalgia and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis - (Full text)
- 2018, Culturing Adult Stem Cells for Cell-Based Therapeutics: Neuroimmune Applications - (Full text)
- 2019, Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking back on Treatments - (Abstract)
- 2019, Epigenetic Components of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Uncover Potential Transposable Element Activation - (Full text)
Talks and interviews[edit | edit source]
- 2016, Speaker at the 11th Invest in ME International ME Conference on "Molecular Biomarkers of Myalgic Encephalomyelitis" - DVD available
- 2018, UK CFS/ME Research Collaborative Conference - MRC Funded Update: Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of Chronic Fatigue Syndrome
See also[edit | edit source]
References[edit | edit source]
- "Elisa Oltra García: "Trabajamos en el desarrollo de un test válido y objetivo para el diagnóstico de la fibromialgia"". www.oei.es. Retrieved May 2, 2019.
- "2017 Ramsay Award Program Results". Solve ME/CFS Initiative. Retrieved May 2, 2019.
- "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved Oct 11, 2019.
- "Action CA15111". COST. Retrieved Jul 16, 2019.
- Scheibenbogen, Carmen; Freitag, Helma; Blanco, Julià; Capelli, Enrica; Lacerda, Eliana; Authier, Jerome; Meeus, Mira; Castro Marrero, Jesus; Nora-Krukle, Zaiga; Oltra, Elisa; Strand, Elin Bolle; Shikova, Evelina; Sekulic, Slobodan; Murovska, Modra (Jul 26, 2017). "The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE". Journal of Translational Medicine. 15 (1). doi:10.1186/s12967-017-1263-z. ISSN 1479-5876. PMC . PMID 28747192.
- Trivedi, Malav S.; Oltra, Elisa; Sarria, Leonor; Rose, Natasha; Beljanski, Vladimir; Fletcher, Mary Ann; Klimas, Nancy G.; Nathanson, Lubov (Jul 2018). "Identification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-associated DNA methylation patterns". PlosOne. doi:10.1371/journal.pone.0201066.
- Espejo, José; García-Escudero, María; Oltra, Elisa (Sep 9, 2018). "Unraveling the Molecular Determinants of Manual Therapy: An Approach to Integrative Therapeutics for the Treatment of Fibromyalgia and Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Molecular Sciences. 19 (9): 2673. doi:10.3390/ijms19092673.
- Moreno-Manzano, Victoria; Oltra Garcia, Elisa (Nov 5, 2018). "Culturing adult stem cells for cell-based therapeutics: Neuroimmune Applications" (PDF). Retrieved Nov 16, 2018.
- Eloy Almenar-Pérez,; Sánchez-Fito, Teresa; Ovejero, Tamara; Nathanson, Lubov; Oltra, Elisa (Feb 14, 2019). "Impact of Polypharmacy on Candidate Biomarker miRNomes for the Diagnosis of Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Striking back on Treatments". Preprints (2019020134). doi:10.20944/preprints201902.0134.v1.
- Almenar-Pérez, Eloy; Ovejero, Tamara; Sánchez-Fito, Teresa; Espejo, José A.; Nathanson, Lubov; Oltra, Elisa (Apr 2019). "Epigenetic Components of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Uncover Potential Transposable Element Activation". Clinical Therapeutics. 41 (4): 675–698. doi:10.1016/j.clinthera.2019.02.012.
- "Invest in ME Research - UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved Jul 16, 2019.
myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.
chronic fatigue syndrome (CFS) - A controversial term, invented by the U.S. Centers for Disease Control, that generally refers to a collection of symptoms as “fatigue”. There have been multiple attempts to come up with a set of diagnostic criteria to define this term, but few of those diagnostic criteria are currently in use. Previous attempts to define this term include the Fukuda criteria and the Oxford criteria. Some view the term as a useful diagnostic category for people with long-term fatigue of unexplained origin. Others view the term as a derogatory term borne out of animus towards patients. Some view the term as a synonym of myalgic encephalomyelitis, while others view myalgic encephalomyelitis as a distinct disease.